ABBVIE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?
ABBVIE has one hundred and thirty-eight approved drugs.
There are two hundred and twenty-nine US patents protecting ABBVIE drugs.
There are two thousand seven hundred and twenty-two patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-one supplementary protection certificates in nineteen countries.
Summary for ABBVIE
International Patents: | 2722 |
US Patents: | 229 |
Tradenames: | 124 |
Ingredients: | 99 |
NDAs: | 138 |
Drug Master File Entries: | 1 |
Patent Litigation for ABBVIE: | See patent lawsuits for ABBVIE |
Drugs and US Patents for ABBVIE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | 9,499,545 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Abbvie | DUOPA | carbidopa; levodopa | SUSPENSION;ENTERAL | 203952-001 | Jan 9, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Abbvie | NALBUPHINE HYDROCHLORIDE | nalbuphine hydrochloride | INJECTABLE;INJECTION | 020200-001 | Mar 12, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | 9,539,251 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ABBVIE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | POWDER;INTRAMUSCULAR | 020263-003 | Apr 16, 1993 | 4,728,721 | ⤷ Try a Trial |
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | 7,141,593*PED | ⤷ Try a Trial |
Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-001 | Aug 30, 2012 | 8,110,553 | ⤷ Try a Trial |
Abbvie | DEPAKOTE ER | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 021168-002 | May 31, 2002 | 6,720,004*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Ophthalmic Solution | 0.2%/0.5% | ➤ Subscribe | 2008-11-21 |
➤ Subscribe | Extended-release Tablets | 4 mg/ 240 mg | ➤ Subscribe | 2007-07-24 |
➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
➤ Subscribe | Ophthalmic Solution | 0.03% | ➤ Subscribe | 2008-12-22 |
➤ Subscribe | Tablets | 1 mg, 2 mg and 4 mg | ➤ Subscribe | 2004-10-04 |
➤ Subscribe | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2010-12-07 |
➤ Subscribe | Delayed-release Capsules | 45 mg | ➤ Subscribe | 2009-09-02 |
➤ Subscribe | Tablets | 12.5 mg, 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2013-01-14 |
➤ Subscribe | Capsules | 4 mcg | ➤ Subscribe | 2008-08-25 |
➤ Subscribe | Capsules | 5 mg | ➤ Subscribe | 2005-08-17 |
➤ Subscribe | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg | ➤ Subscribe | 2017-07-25 |
➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | Gel | 10% | ➤ Subscribe | 2014-06-19 |
➤ Subscribe | Injection | 10 mg/mL (2 mL) | ➤ Subscribe | 2018-07-13 |
➤ Subscribe | Extended-release Capsules | 28 mg | ➤ Subscribe | 2013-06-12 |
➤ Subscribe | Tablets | 2.5 mg/200 mg | ➤ Subscribe | 2006-02-24 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2009-08-12 |
➤ Subscribe | Delayed-release Tablets | 800 mg | ➤ Subscribe | 2011-07-13 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | ➤ Subscribe | 2013-06-10 |
➤ Subscribe | Tablets | 10 mg, 20 mg, and 40 mg | ➤ Subscribe | 2015-01-21 |
➤ Subscribe | Ophthalmic Solution | 0.40% | ➤ Subscribe | 2005-01-28 |
➤ Subscribe | Extended-release Tablets | 250 mg | ➤ Subscribe | 2004-05-03 |
➤ Subscribe | Capsules | 21 mg/10 mg | ➤ Subscribe | 2016-09-23 |
➤ Subscribe | Opthalmic Solution | 0.45% | ➤ Subscribe | 2011-08-24 |
➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-12-22 |
➤ Subscribe | Tablets | 100 mg/25 mg | ➤ Subscribe | 2008-12-23 |
➤ Subscribe | Ophthalmic Solution | 0.15% | ➤ Subscribe | 2006-11-03 |
➤ Subscribe | Extended-release Tablets | 1 mg/240 mg | ➤ Subscribe | 2008-02-20 |
➤ Subscribe | Capsules | 145 mcg and 290 mcg | ➤ Subscribe | 2016-08-30 |
➤ Subscribe | Ophthalmic Solution | 0.25% | ➤ Subscribe | 2014-07-30 |
➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2017-06-09 |
➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Ophthalmic Solution | 0.01% | ➤ Subscribe | 2011-04-05 |
➤ Subscribe | Delayed-release Capsules | 400 mg | ➤ Subscribe | 2014-06-17 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Capsules | 1 mcg and 2 mcg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Topical Solution | 0.03% | ➤ Subscribe | 2010-05-03 |
➤ Subscribe | Delayed-release Capsules | 135 mg | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 400 mg and 600 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Gel | 7.5% | ➤ Subscribe | 2017-02-13 |
➤ Subscribe | Capsules | 10 mg and 20 mg | ➤ Subscribe | 2005-03-30 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | ➤ Subscribe | 2013-08-16 |
➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
➤ Subscribe | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | ➤ Subscribe | 2009-08-04 |
➤ Subscribe | Suppository | 1000 mg | ➤ Subscribe | 2013-05-24 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg | ➤ Subscribe | 2013-06-17 |
➤ Subscribe | Tablets | 5 mg/200 mg | ➤ Subscribe | 2005-05-27 |
➤ Subscribe | Injection | 400 mg/vial and 600 mg/vial | ➤ Subscribe | 2014-10-29 |
➤ Subscribe | Extended-release Tablet | 500 mg | ➤ Subscribe | 2010-12-06 |
➤ Subscribe | Capsules | 14 mg/10 mg and 28 mg/10 mg | ➤ Subscribe | 2015-05-18 |
➤ Subscribe | Opthalmic Solution | 0.45% | ➤ Subscribe | 2011-08-23 |
➤ Subscribe | Extended-release Tablets | 500 mg | ➤ Subscribe | 2005-02-08 |
➤ Subscribe | Capsules | 7 mg/10 mg | ➤ Subscribe | 2016-09-26 |
➤ Subscribe | Ophthalmic Solution | 0.10% | ➤ Subscribe | 2006-12-20 |
➤ Subscribe | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | ➤ Subscribe | 2007-11-09 |
➤ Subscribe | Oral Solution | 80 mg/20 mg per mL | ➤ Subscribe | 2014-06-19 |
International Patents for ABBVIE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2753387 | ⤷ Try a Trial |
Canada | 2942823 | ⤷ Try a Trial |
European Patent Office | 1991205 | ⤷ Try a Trial |
Slovenia | 2638042 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ABBVIE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3141251 | 301099 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
1725537 | CR 2017 00008 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921 |
2673237 | LUC00111 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326 |
2203431 | 15C0013 | France | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.